Cetera Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Cetera Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-11,448	Closed	-$30K	–	1015
2018 Q3	$30K	Buy	11,448 +448	+4%	+$1.1K	﹤0.01%	942
2018 Q2	$25K	Hold	11,000	–	–	﹤0.01%	857
2018 Q1	$32K	Hold	11,000	–	–	﹤0.01%	765
2017 Q4	$30K	Hold	11,000	–	–	﹤0.01%	764
2017 Q3	$37K	Hold	11,000	–	–	﹤0.01%	816
2017 Q2	$27K	Hold	11,000	–	–	﹤0.01%	803
2017 Q1	$25K	Sell	11,000 -4,000	-27%	-$8.85K	﹤0.01%	779
2016 Q4	$31K	Hold	15,000	–	–	﹤0.01%	713
2016 Q3	$50K	Sell	15,000 -1,000	-6%	-$3.17K	﹤0.01%	746
2016 Q2	$50K	Sell	16,000 -71,500	-82%	-$238K	﹤0.01%	752
2016 Q1	$291K	Buy	+87,500	New	+$273K	0.02%	534

Other funds holding PDLI

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Cetera Advisors's PDLI Position: Q4 2018 in Review

Cetera Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2018, closing a stake of 11,448 shares — an estimated $30K sold.

Cetera Advisors first reported a position in PDLI in Q1 2016 and held it in 11 quarters. The position peaked at $291K in Q1 2016. 154 funds tracked by Wall St. Rank hold PDLI as of Q4 2018.

Cetera Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2018 after selling out during the quarter.
Cetera Advisors sold 11,448 PDL BioPharma, Inc. shares in Q4 2018, an estimated $30K.
Cetera Advisors first reported a position in PDL BioPharma, Inc. in Q1 2016 and held it in 11 quarters.
Cetera Advisors's PDL BioPharma, Inc. position peaked at $291K in Q1 2016.
154 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2018.

Based on Cetera Advisors's 13F filing for Q4 2018, filed 15 Feb 2019.